<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201024049128N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-09</date_registration>
      <primary_sponsor>Alborz University of Medical Sciences</primary_sponsor>
      <public_title>Effects of topical magnesium sulfate on progression of labor</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effects of topical magnesium sulfate on the active phase and progression of labor in nulliparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>148</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56162</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients are recruited in from referred clientele of Kamali hospital that have inclusion criteria. using the randomized block method, in the form of quadruple blocks in two double-blind intervention groups And control will be assigned. In this way, a part of the table of random numbers is selected and AB code is used for 0 to 4 numbers and BA code is used for 5 to 9 numbers. In this study, code A represents the group receiving magnesium sulfate and code B represents the control group. This randomization are done with Random number generator command of STATA software until reaching determined  sample size . In this special randomized study people are categorized in control and study group with technique of Balanced block randomization, Blinding description: In order to prepare patient's randomly allocated successions, it was placed in sealed envelopes that are designated in 5 digit serial numbers, by a third person who is not involved in the trial. All the envelopes carry this 5 digit serial number and are opened immediately after completion of patient's work-up and basic lab tests and thus categorize them into intervention and control groups. No patient is aware of another's progression or outcome.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Active phase and progression of Labor in nulliparous women.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, after the onset of the active phase, which is dilated 3-5 cm with active uterine contractions and having a Bishop score of 5, the researcher pours 10 cc of 50% magnesium sulfate into the cervix from the fingertips with a 10 cc syringe by the examiner. If a ruptured bladder is seen, 10 cc of magnesium sulfate is poured on the cervix again. Generic drug used is magnesium sulfate injection parenteral 10 % 50milliliter (infu-magnesol); made by shahid ghazi pharmaceuticals company; IRC 6210969267810048. Intervention 2: Control group : we perform no special intervention on them just measure the above mentioned factors without magnesium sulphate.Then the data are comprised with the data of intevention group after entering in the analyzing program.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Rakhshafar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali Hospital; Kamali Alley; Shohada Square; Shahid Beheshti Street</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149779453</zip>
        <telephone>+98 26 3222 2021</telephone>
        <email>rakhshafar.reza@gmail.com</email>
        <affiliation>Alborz University of Medical Science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bita Badehnoosh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali Hospital; Kamali Alley; Shohada Square; Shahid Beheshti Street</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149779453</zip>
        <telephone>+98 26 3222 2021</telephone>
        <email>b_badehnoosh@yahoo.com</email>
        <affiliation>Alborz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women with gestational age of 37 to 42 weeks
First labor
Single fetus weighting between 3.5 - 4 kg
Low risk, non-induced labor
BMI of the mother being between 19.8 and 30 kg/m2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Any sign indicating fetal heart rate abnormalities, placenta abruption, cord prolapse  or anything that pregnancy is high risk
Cephalopelvic disproportion
Mothers' chronic underlying disease like anemia, hemophilia, cardiopulmonary or neuromuscular disease
Any sign of allergy or toxicity caused by magnesium sulfate</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, after the onset of the active phase, which is dilated 3-5 cm with active uterine contractions and having a Bishop score of 5, the researcher pours 10 cc of 50% magnesium sulfate into the cervix from the fingertips with a 10 cc syringe by the examiner. If a ruptured bladder is seen, 10 cc of magnesium sulfate is poured on the cervix again. Generic drug used is magnesium sulfate injection parenteral 10 % 50milliliter (infu-magnesol); made by shahid ghazi pharmaceuticals company; IRC 6210969267810048.</i_keyword>
      <i_keyword>Control group : we perform no special intervention on them just measure the above mentioned factors without magnesium sulphate.Then the data are comprised with the data of intevention group after entering in the analyzing program.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fetal station. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Physical examination and recording the data on questionnaire.</prim_outcome>
      <prim_outcome>Cervical dilation. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Physical examination and recording the data on questionnaire.</prim_outcome>
      <prim_outcome>Cervical effacement. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Physical examination and recording the data on questionnaire.</prim_outcome>
      <prim_outcome>Cervical consistency. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Physical examination and recording the data on questionnaire.</prim_outcome>
      <prim_outcome>Cervical position. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Physical examination and recording the data on questionnaire.</prim_outcome>
      <prim_outcome>Bishop score. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Calculated by adding up the scores of the first 5 variables, maximum score of15.</prim_outcome>
      <prim_outcome>Length of the active phase of labor. Timepoint: Every 2 hours until the end of active phase of labor. Method of measurement: Physical examination and recording the data on questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Alborz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-08</approval_date>
        <contact_name>Ethics Committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>Research and Development Department of Alborz University of Medical Sciences, Safarian Ave, 45 Metri Blvd, Karaj, Iran Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
